Movatterモバイル変換


[0]ホーム

URL:


CA2325541A1 - Extended release formulations of erythromycin derivatives - Google Patents

Extended release formulations of erythromycin derivatives
Download PDF

Info

Publication number
CA2325541A1
CA2325541A1CA002325541ACA2325541ACA2325541A1CA 2325541 A1CA2325541 A1CA 2325541A1CA 002325541 ACA002325541 ACA 002325541ACA 2325541 ACA2325541 ACA 2325541ACA 2325541 A1CA2325541 A1CA 2325541A1
Authority
CA
Canada
Prior art keywords
extended release
release formulations
erythromycin derivatives
composition
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002325541A
Other languages
French (fr)
Other versions
CA2325541C (en
Inventor
Laman A. Al-Razzak
Sheri L. Crampton
Linda E. Gustavson
Ho-Wah Hui
Nelly Milman
Susan J. Semla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=25681240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2325541(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/838,900external-prioritypatent/US6010718A/en
Application filed by IndividualfiledCriticalIndividual
Priority to CA002358395ApriorityCriticalpatent/CA2358395C/en
Publication of CA2325541A1publicationCriticalpatent/CA2325541A1/en
Application grantedgrantedCritical
Publication of CA2325541CpublicationCriticalpatent/CA2325541C/en
Anticipated expirationlegal-statusCritical
Expired - Fee Relatedlegal-statusCriticalCurrent

Links

Landscapes

Abstract

An extended release pharmaceutical composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer, the composition has an improved taste profile as compared to an immediate release composition of the erythromycin derivative.
CA002325541A1997-04-111998-03-06Extended release formulations of erythromycin derivativesExpired - Fee RelatedCA2325541C (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CA002358395ACA2358395C (en)1997-04-111998-03-06Extended release formulations of erythromycin derivatives

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US08/838,900US6010718A (en)1997-04-111997-04-11Extended release formulations of erythromycin derivatives
US08/838,9001997-04-11
CA002285266ACA2285266C (en)1997-04-111998-03-06Extended release formulations of erythromycin derivatives

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
CA002285266ADivisionCA2285266C (en)1997-04-111998-03-06Extended release formulations of erythromycin derivatives

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
CA002358395ADivisionCA2358395C (en)1997-04-111998-03-06Extended release formulations of erythromycin derivatives

Publications (2)

Publication NumberPublication Date
CA2325541A1true CA2325541A1 (en)1998-10-22
CA2325541C CA2325541C (en)2001-10-09

Family

ID=25681240

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CA002325541AExpired - Fee RelatedCA2325541C (en)1997-04-111998-03-06Extended release formulations of erythromycin derivatives

Country Status (1)

CountryLink
CA (1)CA2325541C (en)

Also Published As

Publication numberPublication date
CA2325541C (en)2001-10-09

Similar Documents

PublicationPublication DateTitle
CA2265767A1 (en)Stable pharmaceutical composition including 4,5-epoxy-morphinan derivative
CA2285266A1 (en)Extended release formulations of erythromycin derivatives
CA2263404A1 (en)Pharmaceutical composition comprising coenzyme q10
AU698992B2 (en)Pharmaceutical, orally applicable composition
AU2001237526A1 (en)Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
AU5975999A (en)Diarylmethylidene furan derivatives as drugs with anti-inflammatory, analgesic and chemopreventive properties
AU3932999A (en)Pyrazoline derivatives, their preparation and application as medicaments
AU5036999A (en)Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
AU7962200A (en)Novel indole derivatives and drugs containing the same as the active ingredient
AU7588696A (en)Pyrido{2, 3-D} pyrimidine derivatives and pharmaceutical compositions thereof
AU3794795A (en)Pharmaceutical, orally applicable composition
AU3794595A (en)Pharmaceutical, orally applicable composition
AU5487398A (en)Pyrrole derivatives, their preparation and pharmaceutical compositions containing them
AU4304400A (en)Novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives
AU2001292331A2 (en)5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2773597A (en)Pharmaceutical compositions for the sustained release of insoluble active principles
IL121969A0 (en)10,13,15-trioxatricyclo[9.2.1.1.9.6]-pentadecanone derivatives their preparation and pharmaceutical compositions containing them
CA2337667A1 (en)Dextran-leptin conjugates, pharmaceutical compositions and related methods
AU3693797A (en)1,3-dimethyl-5-fluoro-pyrazole-4-carboxamide derivatives, their preparation and their use as microbicides
AU1650501A (en)1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
AU5368699A (en)Derivatives of triptolide, and preparation and uses thereof
EP1059304A4 (en)Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
CA2358395A1 (en)Extended release formulations of erythromycin derivatives
CA2325541A1 (en)Extended release formulations of erythromycin derivatives
AU4136897A (en)2,3-dihydrobenzofuran derivative and hepatopathy remedy comprising the same as active ingredient

Legal Events

DateCodeTitleDescription
EEERExamination request
MKLALapsed

[8]ページ先頭

©2009-2025 Movatter.jp